GLP-1 Goes Everywhere
Giordano Bruno Contestabile@giordanobc
· 1
−0.8%
since Sep 30
The idea
I believe GLP-1 adoption will be as transformative as AI, moving faster and broader than most expect. So the biggest slice of this basket sits with the supply bottleneck, the peptide manufacturing, injector, and fill-finish companies that hit their limits first when demand outpaces forecasts, alongside the drugmakers themselves, both leaders and cheaper challengers. Smaller positions cover the channels getting drugs to patients and the ripple businesses like nutrition, gyms, and sleep care that benefit as treatment scales.
What it owns
- The factories, pens, and cartridges that can't keep up if adoption runs faster than assumed. · West Pharmaceutical ServicesIt makes the elastomer components inside nearly every injector pen, so demand spikes jump here before drugmakers report sales., Thermo Fisher ScientificIt sells the fill-finish capacity where drug gets put into vials and pens, the step that breaks first when demand outruns supply., Stevanato GroupIt makes the glass cartridges that go inside GLP-1 pens, a pure play on the supply layer most likely to break first., DanaherIt sells the bioprocessing equipment drugmakers buy when expanding peptide manufacturing during a capacity race., Becton DickinsonIt supplies the autoinjector pens themselves, so every incremental patient on an injectable GLP-1 is a device sold., RepligenIt makes the purification tools used in peptide manufacturing, one of the bottlenecks demand hits first.34%
- The companies selling the drugs, from the two giants to the cheaper challengers still in trials. · Eli LillyIt makes the only GLP-1 pill approved on the market, which reaches far more people than injections ever could., Novo NordiskIt holds the biggest installed base of GLP-1 patients through Wegovy and Ozempic, so broader adoption lifts it even without a pill., AmgenIts monthly-dose candidate pulls in people who won't do weekly injections if adoption is broader than assumed., Viking TherapeuticsIt has no approved product yet, but pipeline data competitive enough to move hardest if the market decides demand is bigger than assumed., Structure TherapeuticsIt is racing to market with a cheaper oral GLP-1 that matters if adoption goes broad enough for tens of millions of new patients., AltimmuneIt is an asymmetric bet on weight loss that spares muscle, a real differentiator if GLP-1 becomes something tens of millions use for years.33%
- Businesses that win when millions of people start losing weight. · Planet FitnessIt is the budget gym people join once the weight starts coming off, a second-order winner if adoption runs broader than assumed., BellRing BrandsPeople on GLP-1s eat less but need to protect muscle, and its protein shakes are the cheapest answer for tens of millions of new patients., ResMedIt wins on the ripple because GLP-1 patients get diagnosed with sleep apnea at higher rates on the way to treatment., Abbott LaboratoriesIts medical nutrition business sells directly to people managing muscle and nutrition on GLP-1s.15%
- The telehealth companies that turn demand into prescriptions, the broadest on-ramp for new patients. · Hims & Hers HealthIt gets GLP-1s to people who can't or won't go through traditional doctors, where broader-than-assumed adoption shows up first., LifeMDIt is a weight-care telehealth business that grows fastest if adoption goes broad and access to branded drugs stays intact.8%
- Cash10%